Good news keeps on coming at the beginning of the year! Suzhou Kintor Pharmaceuticals Co., Ltd. and Predicine, Inc announced that they had signed a global strategic cooperation agreement to have in-depth and full cross-border cooperation in technology, resources and data in the areas of biomarkers and clinical trial of global new drugs to jointly create a new international landscape of biomarkers companion diagnostic and clinical development of precision new drugs.
Predicine is a global healthcare company focusing on precision medical diagnosis and it operating simultaneously in China and the U.S. It has developed the industry’s first RNA+DNA combined liquid biopsy “Gene RADAR” patent technology and biomarker based “global precision clinical trial solution”. Currently, it works with a number of internationally renowned pharmaceutical companies to support multicenter clinical trials of new drugs which are simultaneously conducted around the world, including China, the U.S., Europe, Asia and Australia. In the past two years, both Kintor and Predicine parties had fruitful business cooperation in the clinical trial of prostate-cancer and breast-cancer screening in China and the U.S. and have established a good relationship based on mutual support and trust.
Kintor Pharma focuses on prostate cancer, breast cancer and liver cancer which are the three major cancers with a high incidence rate in the world. Its self-developed Proxalutamide is the first pilot drug approved by MAH (Marketing Authorization Holder) in Jiangsu province, and also the first innovative drug in China to participate in MAH pilot. It is mainly applied in the treatment of prostate cancer and TNBC, and its Phase I and Phase II clinical trials are currently being carried out in both the U.S. and China.
It generally takes 10 years for the successful development of a new cancer drug internationally which costs US$2.6bn on average. In the light of the long period, high risk and expensive cost for the development of a new anti-tumor drug, Kintor Pharma and Predicine will strategically cooperate in biomarker-centered precision clinical trials around the globe. With cooperation between the laboratories with international standards of CLIA and CAP in Silicon Valley and Shanghai, both parties will accurately screen and monitor the patients undergoing clinical trials, shorten the time for clinical trials and improve the success rate of new drug R&D. Unlike traditional CRO model which featuring simple sample detection services, the cooperation between Predicine and Kintor Pharma will cover a wide range of activities including initial joint participation in the design of clinical trials, management of the entire sample collection & processing, biomarker detection services, bioinformatics analysis, comprehensive data analysis and clinical strategies as well as the development of companion diagnostic kits supporting the submission of new drugs for CFDA and FDA approvals.
The latest cancer statistics show that China has 4.29 million new cancer cases, accounting for nearly 1/3 of the world’s 1,400 million cancer cases. Following implementation of the “2030 Healthy China” policy in 2017, CFDA decisively launched a series of favorable policies to promote the new drug development in China over the past year. The global strategic cooperation between Predicine and Kintor Pharma will form the first exemplary strong alliance between biomarker company and new drug development company, jointly creating a new international trend of new drugs development.
Founded in 2015, Predicine operates CLIA and CAP international standards laboratories in both Silicon Valley in U.S and Shanghai, China. Its team members come from various world first-class industrial and academic institutions. Its main businesses covered early cancer screening, clinical medication guidance and clinical development of new drugs.
Through its patented RNA+DNA combined liquid biopsy “Gene Radar” technology, Predicine not only provides a professional platform on one-stop and all-around biomarker detection and data analysis, but also a biomarker-based “global precision clinical trial solution” for its institutional clients in the global pharmaceutical industry. It has now conducted biomarker-based precision new drugs clinical trials with 25 internationally renowned pharmaceutical companies (including 8 top 500 enterprises in the world) to support the multicenter clinical trials of new drugs which are simultaneously conducted around the world including China, the U.S., Europe, Asia and Australia.